AbbVie announced the FDA has approved Skyrizi (risankizumab-rzaa) for adults with moderately to severely active ulcerative colitis, making it the first IL-23 specific inhibitor approved for both moderate… read more.
On 14 December 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product… read more.
Eli Lilly and Company announced that the FDA has approved Omvoh (mirikizumab-mrkz) infusion (300 mg/15 mL)/injection (100 mg/mL), the first and only interleukin-23p19 (IL-23p19) antagonist for the treatment… read more.
Frequent use of antibiotics may heighten the risk of inflammatory bowel disease—Crohn’s disease and ulcerative colitis—among the over 40s, suggests research published online in the journal Gut. The risk… read more.
Adopting and maintaining a healthy lifestyle might prevent up to 60% of inflammatory bowel disease cases—Crohn’s disease and ulcerative colitis—finds a large international study, published online in the… read more.
Inflammatory bowel disease is a risk factor for giving birth preterm even when in apparent disease remission, a University of Gothenburg study shows. If corroborated, the results may… read more.
Pregnant women with inflammatory bowel disease (IBD) and their babies face increased risks and complications compared to pregnant women without IBD. Those are the findings from a new… read more.
The more antibiotics prescribed to patients 60 and older, the more likely they were to develop inflammatory bowel disease, suggesting antibiotic use could explain some of the growth… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
